Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 110

1.

Multidrug-Resistant Staphylococcus epidermidis Ventriculostomy-Related Infection Successfully Treated by Intravenous Ceftaroline after Failure of Daptomycin Treatment.

Roujansky A, Martin M, Gomart C, Hulin A, Mounier R.

World Neurosurg. 2020 Apr;136:221-225. doi: 10.1016/j.wneu.2020.01.013. Epub 2020 Jan 10.

PMID:
31931253
2.

Deficiency of Circulating Monocytes Ameliorates the Progression of Myxomatous Valve Degeneration in Marfan Syndrome.

Kim AJ, Xu N, Umeyama K, Hulin A, Ponny SR, Vagnozzi RJ, Green EA, Hanson P, McManus BM, Nagashima H, Yutzey KE.

Circulation. 2020 Jan 14;141(2):132-146. doi: 10.1161/CIRCULATIONAHA.119.042391. Epub 2020 Jan 13.

PMID:
31928435
3.

Patients' perspectives after switching from infliximab to biosimilar CT-P13 in patients with inflammatory bowel disease: A 12-month prospective cohort study.

Petitdidier N, Tannoury J, de'Angelis N, Gagniere C, Hulin A, Rotkopf H, Mesli F, Brunetti F, Sobhani I, Amiot A.

Dig Liver Dis. 2019 Dec;51(12):1652-1660. doi: 10.1016/j.dld.2019.08.020. Epub 2019 Nov 11.

PMID:
31718934
4.

Mechanical strain induces a pro-fibrotic phenotype in human mitral valvular interstitial cells through RhoC/ROCK/MRTF-A and Erk1/2 signaling pathways.

Blomme B, Deroanne C, Hulin A, Lambert C, Defraigne JO, Nusgens B, Radermecker M, Colige A.

J Mol Cell Cardiol. 2019 Oct;135:149-159. doi: 10.1016/j.yjmcc.2019.08.008. Epub 2019 Aug 20.

5.

Durability of antimicrobial activity of antibiotic-impregnated external ventricular drains: a prospective study.

Mounier R, Lang E, Hulin A, Woerther PL, Lobo D, Martin M, Bitot V, Flores L, Cherruault M, Jost PH, Couffin S, Tomberli F, Bardon J, Lahiani W, Dhonneur G, Cook F, Lebeaux D.

J Antimicrob Chemother. 2019 Nov 1;74(11):3328-3336. doi: 10.1093/jac/dkz335.

PMID:
31411688
6.

Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma.

Hulin A, Stocco J, Bouattour M.

Clin Pharmacokinet. 2019 Aug;58(8):983-1014. doi: 10.1007/s40262-019-00740-w. Review.

PMID:
31093928
7.

Axitinib pharmacologic therapeutic monitoring reveals severe under-exposure despite titration in patients with metastatic renal cell carcinoma.

Beinse G, Hulin A, Rousseau B.

Invest New Drugs. 2019 Dec;37(6):1289-1291. doi: 10.1007/s10637-019-00743-1. Epub 2019 Feb 26.

PMID:
30806848
8.

Maturation of heart valve cell populations during postnatal remodeling.

Hulin A, Hortells L, Gomez-Stallons MV, O'Donnell A, Chetal K, Adam M, Lancellotti P, Oury C, Potter SS, Salomonis N, Yutzey KE.

Development. 2019 Mar 12;146(12). pii: dev173047. doi: 10.1242/dev.173047.

9.

Profound underdosing of β-lactams in patients with sickle-cell disease.

Cecchini J, Hulin A, Habibi A, Mekontso Dessap A, Razazi K.

J Antimicrob Chemother. 2018 Nov 1;73(11):3211-3212. doi: 10.1093/jac/dky312. No abstract available.

PMID:
30059983
10.

Pregnancy exposure to atmospheric pollution and meteorological conditions and placental DNA methylation.

Abraham E, Rousseaux S, Agier L, Giorgis-Allemand L, Tost J, Galineau J, Hulin A, Siroux V, Vaiman D, Charles MA, Heude B, Forhan A, Schwartz J, Chuffart F, Bourova-Flin E, Khochbin S, Slama R, Lepeule J; EDEN mother-child cohort study group.

Environ Int. 2018 Sep;118:334-347. doi: 10.1016/j.envint.2018.05.007. Epub 2018 Jun 21.

PMID:
29935799
11.

Advances in Pathophysiology of Calcific Aortic Valve Disease Propose Novel Molecular Therapeutic Targets.

Hulin A, Hego A, Lancellotti P, Oury C.

Front Cardiovasc Med. 2018 Mar 14;5:21. doi: 10.3389/fcvm.2018.00021. eCollection 2018.

12.

Macrophage Transitions in Heart Valve Development and Myxomatous Valve Disease.

Hulin A, Anstine LJ, Kim AJ, Potter SJ, DeFalco T, Lincoln J, Yutzey KE.

Arterioscler Thromb Vasc Biol. 2018 Mar;38(3):636-644. doi: 10.1161/ATVBAHA.117.310667. Epub 2018 Jan 18.

13.

Delayed and short course of rapamycin prevents organ rejection after allogeneic liver transplantation in rats.

Hamdani S, Thiolat A, Naserian S, Grondin C, Moutereau S, Hulin A, Calderaro J, Grimbert P, Cohen JL, Azoulay D, Pilon C.

World J Gastroenterol. 2017 Oct 14;23(38):6962-6972. doi: 10.3748/wjg.v23.i38.6962.

14.

Determination of hydroxyurea in human plasma by HPLC-UV using derivatization with xanthydrol.

Legrand T, Rakotoson MG, Galactéros F, Bartolucci P, Hulin A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Oct 1;1064:85-91. doi: 10.1016/j.jchromb.2017.09.008. Epub 2017 Sep 7.

PMID:
28915422
15.

Hypoxia promotes primitive glycosaminoglycan-rich extracellular matrix composition in developing heart valves.

Amofa D, Hulin A, Nakada Y, Sadek HA, Yutzey KE.

Am J Physiol Heart Circ Physiol. 2017 Dec 1;313(6):H1143-H1154. doi: 10.1152/ajpheart.00209.2017. Epub 2017 Aug 25.

16.

Plasma concentrations of atovaquone given to immunocompromised patients to prevent Pneumocystis jirovecii.

Robin C, Lê MP, Melica G, Massias L, Redjoul R, Khoudour N, Leclerc M, Beckerich F, Maury S, Hulin A, Cordonnier C.

J Antimicrob Chemother. 2017 Sep 1;72(9):2602-2606. doi: 10.1093/jac/dkx198.

PMID:
28651341
17.

Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.

Allard M, Khoudour N, Rousseau B, Joly C, Costentin C, Blanchet B, Tournigand C, Hulin A.

J Pharm Biomed Anal. 2017 Aug 5;142:42-48. doi: 10.1016/j.jpba.2017.04.053. Epub 2017 May 1.

PMID:
28494338
18.

Sequential cyclophosphamide-bortezomib-dexamethasone unmasks the harmful cardiac effect of dexamethasone in primary light-chain cardiac amyloidosis.

Le Bras F, Molinier-Frenkel V, Guellich A, Dupuis J, Belhadj K, Guendouz S, Ayad K, Colombat M, Benhaiem N, Tissot CM, Hulin A, Jaccard A, Damy T.

Eur J Cancer. 2017 May;76:183-187. doi: 10.1016/j.ejca.2017.02.004. Epub 2017 Mar 20.

PMID:
28334621
19.

Prophylactic Anticonvulsants in Intracerebral Hemorrhage.

Mackey J, Blatsioris AD, Moser EAS, Carter RJL, Saha C, Stevenson A, Hulin AL, O'Neill DP, Cohen-Gadol AA, Leipzig TJ, Williams LS.

Neurocrit Care. 2017 Oct;27(2):220-228. doi: 10.1007/s12028-017-0385-8.

20.

Are Idiopathic Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Related to Drugs in Food? The Example of Phenylbutazone.

Haddad C, Chosidow O, Valeyrie-Allanore L, Ghaleh B, Legrand T, Mockenhaupt M, Barau C, Khoudour N, Sekula P, Wolkenstein P, Hulin A.

J Invest Dermatol. 2017 May;137(5):1179-1181. doi: 10.1016/j.jid.2016.11.041. Epub 2017 Jan 17. No abstract available.

21.

Loss of Axin2 results in impaired heart valve maturation and subsequent myxomatous valve disease.

Hulin A, Moore V, James JM, Yutzey KE.

Cardiovasc Res. 2017 Jan;113(1):40-51. doi: 10.1093/cvr/cvw229. Epub 2016 Nov 7.

22.

Is First-Line Vancomycin Still the Best Option to Treat Staphylococcus Health Care-Associated Meningitis?

Mounier R, Lobo D, Hulin A, Nebbad B, Cook F, Dhonneur G.

World Neurosurg. 2017 Mar;99:812.e1-812.e5. doi: 10.1016/j.wneu.2016.12.076. Epub 2016 Dec 27.

PMID:
28034813
23.

Disparities and guideline adherence in drugs of abuse screening in intracerebral hemorrhage.

Tormoehlen LM, Blatsioris AD, Moser EA, Carter RJ, Stevenson A, Ofner S, Hulin AL, O'Neill DP, Cohen-Gadol AA, Leipzig TJ, Williams LS, Mackey J.

Neurology. 2017 Jan 17;88(3):252-258. doi: 10.1212/WNL.0000000000003505. Epub 2016 Dec 7.

24.

Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children.

Frémond ML, Rodero MP, Jeremiah N, Belot A, Jeziorski E, Duffy D, Bessis D, Cros G, Rice GI, Charbit B, Hulin A, Khoudour N, Caballero CM, Bodemer C, Fabre M, Berteloot L, Le Bourgeois M, Reix P, Walzer T, Moshous D, Blanche S, Fischer A, Bader-Meunier B, Rieux-Laucat F, Crow YJ, Neven B.

J Allergy Clin Immunol. 2016 Dec;138(6):1752-1755. doi: 10.1016/j.jaci.2016.07.015. Epub 2016 Aug 20. No abstract available.

26.

Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.

Lavaud P, Rousseau B, Ajgal Z, Arrondeau J, Huillard O, Alexandre J, Hulin A, Goldwasser F.

Breast Cancer Res Treat. 2016 May;157(1):191-2. doi: 10.1007/s10549-016-3798-8. Epub 2016 Apr 22. No abstract available.

PMID:
27106482
27.

New use for an old drug: COX-independent anti-inflammatory effects of sulindac in models of cystic fibrosis.

Rocca J, Manin S, Hulin A, Aissat A, Verbecq-Morlot W, Prulière-Escabasse V, Wohlhuter-Haddad A, Epaud R, Fanen P, Tarze A.

Br J Pharmacol. 2016 Jun;173(11):1728-41. doi: 10.1111/bph.13464. Epub 2016 Apr 21.

28.

Does fine sediment source as well as quantity affect salmonid embryo mortality and development?

Sear DA, Jones JI, Collins AL, Hulin A, Burke N, Bateman S, Pattison I, Naden PS.

Sci Total Environ. 2016 Jan 15;541:957-968. doi: 10.1016/j.scitotenv.2015.09.155. Epub 2015 Nov 11.

PMID:
26473698
29.

New biomarkers for primary mitral regurgitation.

Deroyer C, Magne J, Moonen M, Le Goff C, Dupont L, Hulin A, Radermecker M, Colige A, Cavalier E, Kolh P, Pierard L, Lancellotti P, Merville MP, Fillet M.

Clin Proteomics. 2015 Sep 24;12:25. doi: 10.1186/s12014-015-9097-2. eCollection 2015.

30.

Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.

Amiot A, Hulin A, Belhassan M, Andre C, Gagniere C, Le Baleur Y, Farcet JP, Delchier JC, Hüe S.

Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.

PMID:
26138132
31.

Biological parameters predictive of percent dense red blood cell decrease under hydroxyurea.

Rakotoson MG, Di Liberto G, Audureau E, Habibi A, Fauroux C, Khorgami S, Hulin A, Loric S, Noizat-Pirenne F, Galacteros F, Bartolucci P.

Orphanet J Rare Dis. 2015 May 9;10:57. doi: 10.1186/s13023-015-0272-3.

32.

Loss of β-catenin promotes chondrogenic differentiation of aortic valve interstitial cells.

Fang M, Alfieri CM, Hulin A, Conway SJ, Yutzey KE.

Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2601-8. doi: 10.1161/ATVBAHA.114.304579. Epub 2014 Oct 23.

33.

Health effects of ambient air pollution: do different methods for estimating exposure lead to different results?

Sellier Y, Galineau J, Hulin A, Caini F, Marquis N, Navel V, Bottagisi S, Giorgis-Allemand L, Jacquier C, Slama R, Lepeule J; EDEN Mother–Child Cohort Study Group.

Environ Int. 2014 May;66:165-73. doi: 10.1016/j.envint.2014.02.001. Epub 2014 Mar 2.

PMID:
24598283
34.

Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approach.

Gérard C, Stocco J, Hulin A, Blanchet B, Verstuyft C, Durand F, Conti F, Duvoux C, Tod M.

AAPS J. 2014 May;16(3):379-91. doi: 10.1208/s12248-014-9577-8. Epub 2014 Feb 14.

35.

Tgfβ-Smad and MAPK signaling mediate scleraxis and proteoglycan expression in heart valves.

Barnette DN, Hulin A, Ahmed AS, Colige AC, Azhar M, Lincoln J.

J Mol Cell Cardiol. 2013 Dec;65:137-46. doi: 10.1016/j.yjmcc.2013.10.007. Epub 2013 Oct 21.

36.

Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia.

Delgado L, Giraudier S, Ortonne N, Zehou O, Cordonnier C, Hulin A, Chosidow O, Tulliez M, Valeyrie-Allanore L.

J Am Acad Dermatol. 2013 Nov;69(5):839-840. doi: 10.1016/j.jaad.2013.07.025. No abstract available.

PMID:
24124828
37.

Does consideration of larger study areas yield more accurate estimates of air pollution health effects? An illustration of the bias-variance trade-off in air pollution epidemiology.

Pedersen M, Siroux V, Pin I, Charles MA, Forhan A, Hulin A, Galineau J, Lepeule J, Giorgis-Allemand L, Sunyer J, Annesi-Maesano I, Slama R; ‘EDEN Mother–Child’ Cohort Study Group.

Environ Int. 2013 Oct;60:23-30. doi: 10.1016/j.envint.2013.07.005. Epub 2013 Aug 28.

PMID:
23994839
38.

Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection.

Jenabian MA, Seddiki N, Yatim A, Carriere M, Hulin A, Younas M, Ghadimi E, Kök A, Routy JP, Tremblay A, Sévigny J, Lelievre JD, Levy Y.

PLoS Pathog. 2013;9(4):e1003319. doi: 10.1371/journal.ppat.1003319. Epub 2013 Apr 25.

39.

Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.

Andriamanana I, Gana I, Duretz B, Hulin A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:83-91. doi: 10.1016/j.jchromb.2013.01.037. Epub 2013 Mar 16.

PMID:
23562906
40.

Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data.

Hulin A, Deroanne C, Lambert C, Defraigne JO, Nusgens B, Radermecker M, Colige A.

Cardiovasc Pathol. 2013 Jul-Aug;22(4):245-50. doi: 10.1016/j.carpath.2012.11.001. Epub 2012 Dec 21. Review.

41.

Pregnancy exposure to atmospheric pollutants and placental weight: an approach relying on a dispersion model.

Rahmalia A, Giorgis-Allemand L, Lepeule J, Philippat C, Galineau J, Hulin A, Charles MA, Slama R; EDEN Mother-Child Cohort Study group.

Environ Int. 2012 Nov 1;48:47-55. Epub 2012 Jul 24.

PMID:
22836169
42.

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.

Decaens T, Luciani A, Itti E, Hulin A, Roudot-Thoraval F, Laurent A, Zafrani ES, Mallat A, Duvoux C.

Dig Liver Dis. 2012 Jul;44(7):610-6. doi: 10.1016/j.dld.2012.02.005. Epub 2012 Mar 27.

PMID:
22459565
43.

Metallothionein-dependent up-regulation of TGF-β2 participates in the remodelling of the myxomatous mitral valve.

Hulin A, Deroanne CF, Lambert CA, Dumont B, Castronovo V, Defraigne JO, Nusgens BV, Radermecker MA, Colige AC.

Cardiovasc Res. 2012 Mar 1;93(3):480-9. doi: 10.1093/cvr/cvr337. Epub 2011 Dec 16.

PMID:
22180604
44.

Magnesium-deficiency does not alter calcineurin inhibitors activity in mice.

Hulin A, Lamrani L, Sabbagh F, Tallet A, Lecerf F, Bac P, German-Fattal M.

Transpl Immunol. 2012 Jan;26(1):55-61. doi: 10.1016/j.trim.2011.09.001. Epub 2011 Sep 13.

PMID:
21964379
45.

Effects of discontinuing or continuing ongoing statin therapy in severe sepsis and septic shock: a retrospective cohort study.

Mekontso Dessap A, Ouanes I, Rana N, Borghi B, Bazin C, Katsahian S, Hulin A, Brun-Buisson C.

Crit Care. 2011 Jul 18;15(4):R171. doi: 10.1186/cc10317.

46.

CD39/adenosine pathway is involved in AIDS progression.

Nikolova M, Carriere M, Jenabian MA, Limou S, Younas M, Kök A, Huë S, Seddiki N, Hulin A, Delaneau O, Schuitemaker H, Herbeck JT, Mullins JI, Muhtarova M, Bensussan A, Zagury JF, Lelievre JD, Lévy Y.

PLoS Pathog. 2011 Jul;7(7):e1002110. doi: 10.1371/journal.ppat.1002110. Epub 2011 Jul 7.

47.

[Level of evidence for therapeutic drug monitoring of voriconazole].

Hulin A, Dailly E, Le Guellec C; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 Mar-Apr;66(2):109-14. Epub 2011 Jun 6. Review. French.

PMID:
21635857
48.

Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.

Paule I, Sassi H, Habibi A, Pham KP, Bachir D, Galactéros F, Girard P, Hulin A, Tod M.

Orphanet J Rare Dis. 2011 May 28;6:30. doi: 10.1186/1750-1172-6-30.

49.

[Verification/validation of the performances of analytical method].

Vassault A, Hulin A, Chapuzet E, Arnaud J, Giroud C; membres du sous-groupe 2 analytique de la SFBC.

Ann Biol Clin (Paris). 2010 Dec;68 Spec No 1:247-94. French.

PMID:
21613021
50.

[Level of evidence for therapeutic drug monitoring of everolimus].

Goirand F, Royer B, Hulin A, Saint-Marcoux F; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 Jan-Feb;66(1):57-61. Epub 2011 Apr 7. Review. French.

PMID:
21466779

Supplemental Content

Support Center